Pharmacogenomics and Hypertension: Problems and Prospects

Dear Colleagues,

Arterial hypertension is a complex disorder that has a strong underlying hereditary and environmental basis. Genetic factors are estimated to contribute between 40 and 60% to the underlying pathogenesis. Treatment has remained empiric, control rates are suboptimal, and there is minimal translation of genetics from the bench to the clinic.

Although rare monogenic forms of hypertension with a distinct phenotype were initially well documented and provided specific treatments, the overall genetic risk for hypertension was considered to be polygenetic in origin; however, initial GWAS studies could only explain 2% of the overall risk, which led to a degree of nihilism in relation to the pharmacogenetics of hypertension.

The aim and the scope of this Special Issue are to review and publish cutting-edge research on new developments in the understanding of the genetics of arterial hypertension, the translation of genetic research to the clinic, and future directions for pharmacogenomics.

We are soliciting original articles related to understanding the genetic architecture of hypertension, genetic risk scoring, Mendelian randomization, epigenetics, the pharmacokinetics and pharmacodynamics of antihypertensive drugs, and translational research. We will also consider state-of-the-art manuscripts on the status of pharmacogenomics and future directions.

Prof. Dr. Brian L. Rayner
Prof. Dr. Collet Dandara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hypertension
• pharmacogenomics
• epigenetics
• Mendelian randomization
• genetic risk scores
• pharmacodynamics and pharmacokinetics